Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 1032-1038

  Schwarzenbach, Heidi ^a   Alix Panabières, Catherine ^b   Müller, Imke ^a   Letang, Nicolas ^c   Vendrell, Jean Pierre ^b   Rebillard, Xavier ^c   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LAPEYRONIE HOSPITAL   (France)

^c Clinique Beau Soleil   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CAVEOLIN 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; ERYTHROCYTE BAND 4.9 PROTEIN; HEPATOCYTE NUCLEAR FACTOR 4; HEPATOCYTE NUCLEAR FACTOR 4GAMMA; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ALLELIC IMBALANCE; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GENE FREQUENCY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL;

ALLELIC IMBALANCE; CELL-FREE SYSTEM; DNA, NEOPLASM; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PLASMA; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 61349121505     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1910     Document Type: Article

References (44)

1. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8: 329-40.
2. Pantel K BR. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
3. Riethdorf S, Wikman H, Pantel K. Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008;123:1991 -2006.
4. Schwarzenbach H, Chun FK, Lange I, et al. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer 2007;120:1465-71.
5. Garcia JA, Rosenberg JE, Weinberg V, et al. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int 2007;99:519-24.
6. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-9.
7. Fizazi K, Morat L, Chauveinc L, et al. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol 2007;18:518-21.
8. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005;65:713-8.
9. Medeiros R, Morais A, Vasconcelos A, et al. Endothelial nitric oxide synthase gene polymorphisms and the shedding of circulating tumour cells in the blood of prostate cancer patients. Cancer Lett 2003;189:85-90.
10. Danila DC, Heller G, GignacGA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-8.
11. Alix-Panabieres C, Vendrell JP, Pelle O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007;53:537-9.
12. Alix-Panabieres C, Rebillard X, Brouillet JP, et al. Detection of circulating prostate-specific antigen- secreting cells in prostate cancer patients. Clin Chem 2005;51:1538-41.
13. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-9.
14. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007;635:105-17.
15. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007;1775:181 -232.
16. Jahr S HH, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
17. ChenX, Bonnefoi H, Diebold-Berger S, et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999;5:2297-303.
18. Chun FK, Muller I, Lange I, et al. Circulating tumour- associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 2006;98:544-8.
19. Schwarzenbach H, Muller V, Stahmann N, Pantel K. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann NY Acad Sci 2004;1022:25-32.
20. Muller I, Urban K, Pantel K, Schwarzenbach H. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia. Ann NY Acad Sci 2006;1075:222-9.
21. Schwarzenbach H, Muller V, Beeger C, Gottberg M, Stahmann N, Pantel K. A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer. Breast Cancer Res 2007;9:R66.
22. Coulet F, Blons H, Cabelguenne A, et al. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2000;60:707-11.
23. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells. N Engl J Med 2008;359:366-77.
24. von Knobloch, Konrad L, Barth PJ, et al. Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin Cancer Res 2004;10:1064-73.
25. Muller I, Beeger C, Alix-Panabieres C, Rebillard X, Pantel K, Schwarzenbach H. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. Clin Chem 2008;54:688-96.
26. Alix-Panabieres C, Brouillet JP, Fabbro M, et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 2005;299:177-88.
27. Schwarzenbach H, Chun FK, Muller I, et al. Micro- satellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int 2008;102:253-8.
28. Schmidt B, Anastasiadis AG, Seifert HH, Franke KH, Oya M, Ackermann R. Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade. Anticancer Res 2003;23:3991-9.
29. de Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007;13:3611 -6.
30. Lutchman M, Pack S, Kim AC, et al. Loss of hetero- zygosity on 8p in prostate cancer implicates a role for dematin in tumor progression. Cancer Genet Cytogenet 1999;115:65 -9.
31. Perinchery G, Bukurov N, Nakajima K, Chang J, Li LC, Dahiya R. High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer. Int J Cancer 1999;83:610-4.
32. Gao X, Zacharek A, Salkowski A, et al. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995;55:1002-5.
33. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131 -42.
34. Fernandez PL, Hernandez L, Farre X, Campo E, Cardesa A. Alterations of cell cycle-regulatory genes in prostate cancer. Pathobiology 2002;70:1 -10.
35. Murray MM, Mullan PB, Harkin DP. Role played by BRCA1 in transcriptional regulation in response to therapy. Biochem Soc Trans 2007;35:1342 -6.
36. Murakami YS, Brothman AR, Leach RJ, White RL. Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res 1995;55:3389 -94.
37. Chekmareva MA, Kadkhodaian MM, Hollowell CM, et al. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res 1998;58:4963-9.
38. SchmidtH, DeAngelis G, Eltze E, GockelI, Semjonow A, Brandt B. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 2006;66:8959-65.
39. Holcomb IN, Grove DI, Kinnunen M, et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 2008;68:5599 -608.
40. Klein CA, Holzel D. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 2006;5:1788-98.
41. Ellinger J, Haan K, Heukamp LC, et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008;68:42-9.
42. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037 -43.
43. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187 -98.
44. Roupret M, Hupertan V, Catto JW, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 2008;122:952-6.